# Mechanistic Hypotheses for EVs as Early AD Biomarkers
## The "Prion-Like Templating Cascade" Hypothesis
I propose that disease-specific EV subtypes function as nucleation templates that accelerate pathological protein conversion in a feed-forward manner long before plaque/tangle deposition becomes extensive. Specifically, neurons experiencing early metabolic stress release EVs enriched in oligomeric amyloid-β and phosphorylated tau conformers that seed conversion of naive proteins in recipient cells—including peripheral immune cells accessible via blood sampling. This predicts that: (1) plasma EVs from preclinical AD should show >3-fold enrichment in β-sheet-prone tau epitopes compared to age-matched controls, detectable by conformer-specific biosensors; (2) EV-to-neuron transfer in microfluidic co-cultures should produce 5-10x amplification of pathological tau/Aβ in recipient neurons within 48 hours, quantifiable by high-resolution live imaging; and (3) EV composition should predict cognitive decline trajectory better than static CSF biomarkers, even among cognitively normal APOE4+ individuals. The testable prediction is that blocking EV uptake via heparin sulfate antagonists halts this propagation *in vitro*, providing mechanistic validation.
## The "Glial Licensing" Alternative
Rather than assuming neuronal EVs are primary drivers, I hypothesize that early AD involves a *licensing phase* where astrocytes and microglia release EV populations carrying DAMPs (damage-associated molecular patterns) and pro-inflammatory lipids that prime peripheral immune cells for CNS tropism. These glial EVs carry specific phospholipid signatures (oxidized phosphatidylserine, phosphatidic acid) and cytokine cargo (IL-18, TNF-α) that systemically reshape immune surveillance. This predicts: (1) glial-derived EVs should precede neuronal markers by 3-5 years in longitudinal plasma biobanks; (2) EV phospholipid composition (via lipidomics) should distinguish preclinical AD from healthy aging with >90% sensitivity; and (3) transfer of such EVs to primary monocytes should reprogram them toward an AD-associated phenotype (upregulation of CD11c, IL-1β) without exposure to actual amyloid—a pure EV-driven effect.
## Testable Predictions & Experimental Design
Both hypotheses converge on a critical prediction: **EV biomarkers should outperform current static markers in predicting conversion to MCI specifically in cognitively normal individuals with normal amyloi